EU Regulator Decides Against Tecovirimat SIGA, As An Mpox Therapeutic...

As we mentioned last month, the would-be treatment did no better than placebos, in animal models -- CHMP has declared, at the EMA.

No double-blinded human trials were run, as there were too few Mpox patients (at the time) to evaluate it against.

The path of bio-science is inexorably littered with blind alley detours, as here.

Here's all of that -- from MedScape:

. . .The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that Tecovirimat SIGA should no longer be used for the treatment of mpox.

A review of the antiviral medicine was initiated at the request of the European Commission following evidence from clinical trials suggesting a lack of effectiveness in the treatment of mpox. The CHMP’s decision does not affect the drugs other uses, including in the treatment of smallpox, cowpox, and complications from smallpox vaccines. . . .

Onward, smiling -- to a 90 minute isolation/flotation tank this afternoon [I will report here, scientifically if I am able to regress -- to some primordial soup state(!)] -- then the NCAAs tonight with buddies (at the United Center!), and "No Kings" again marching, down in the 40 degree Chi weather, tomorrow!

नमस्ते